MaxiNovel Pharmaceuticals is Drug Discovery in China that focus on high morbidity business. Founded in 2016. They cover business area such as developer, biotechnology, molecule therapeutic, various type, cancer, disease area, high mortality, high morbidity, no effective treatment, its main product, small molecule target drug, oncology drug, tumor immune drug.
2016
( 8 years old in 2024 )
High Morbidity
-
Room 1005, 10/F, Building A4, Commercial Plaza
No. 181 Science Blvd, Guangzhou Hitech Park
Guangzhou, Guangdong
China
Private
developerbiotechnologymolecule therapeuticvarious typecancerdisease areahigh mortalityhigh morbidityno effective treatmentits main productsmall molecule target drugoncology drugtumor immune drug
* We use standard office opening hours in near MaxiNovel Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
MaxiNovel Pharmaceuticals is Drug Discovery business from China that founded in 2016 (8 years old in 2024), MaxiNovel Pharmaceuticals business is focusing on High Morbidity.
MaxiNovel Pharmaceuticals headquarter office and corporate office address is located in Room 1005, 10/F, Building A4, Commercial Plaza No. 181 Science Blvd, Guangzhou Hitech Park Guangzhou, Guangdong China.
MaxiNovel Pharmaceuticals was founded in China.
In 2024, MaxiNovel Pharmaceuticals is currently focus on high morbidity sector.
Above is snippet of Google Trends for "high morbidity" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with MaxiNovel Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
